文献速递临床试验与 GCP医学人工智能与信息学

SuRxgWell:基于远程医疗的数字认知行为干预用于择期髋膝关节置换术高焦虑抑郁患者的随机对照试验研究方案

SuRxgWell: study protocol for a randomized controlled trial of telemedicine-based digital cognitive behavioral intervention for high anxiety and depression among patients undergoing elective hip and knee arthroplasty surgery.
PubMed 文献 · Trials · 2023-11-09

本研究为随机对照试验,计划纳入术前存在焦虑和/或抑郁症状的原发性单侧全髋或全膝关节置换术患者,以PROMIS简表焦虑4a和/或抑郁4a的T评分≥60为入组标准。受试者按3:1随机分配至常规护理组或RxWell™数字认知行为干预联合常规护理组,主要结局为手术当日焦虑或抑郁症状,采用PROMIS简表、GAD-7和PHQ-8评估。

要点

  • 拟检验数字认知行为干预能否改善关节置换患者术前情绪障碍并减少术后疼痛与阿片类药物需求。
  • 入组标准为PROMIS简表焦虑4a和/或抑郁4a的T评分≥60。
  • 干预组于术前1个月至术后3个月使用RxWell™,主要结局为手术当日焦虑或抑郁症状。

核心结论

  • 本试验将评估数字认知行为干预作为围手术期工具改善大骨科手术前后焦虑和抑郁的可行性,并与教育对照;若被证明有效,可能具有重要临床意义,减少慢性术后疼痛发生率并改善结局。

研究设计与样本

  • 随机对照试验,计划纳入术前有焦虑和/或抑郁症状的原发性单侧全髋或全膝关节置换术患者,按3:1随机分配至常规护理组或RxWell™加常规护理组。
  • 受试者签署知情同意后以PROMIS简表焦虑4a和/或抑郁4a的T评分≥60筛选入组;干预组术前1个月至术后3个月使用SuRxgWell数字认知行为干预。
  • 研究者和受试者设盲,但接触患者的研究协调员和受试者不设盲;主要假设采用意向性治疗分析,主要结局差异采用独立双样本t检验。

主要发现

  • 主要结局为手术当日焦虑或抑郁症状,采用PROMIS简表v1.0焦虑4a/抑郁和广泛性焦虑障碍量表(GAD-7)及患者健康问卷(PHQ-8)测量。
  • 次要结局包括睡眠障碍、疲劳、参与社会角色能力、疼痛干扰、认知功能、疼痛灾难化、躯体功能等健康相关生活质量指标,以及术前和术后疼痛评分、止痛药物使用和骨科功能恢复。
  • 骨科功能恢复采用疼痛灾难化量表、膝关节损伤与骨关节炎结局评分(KOOS)和髋关节损伤与骨关节炎结局评分(HOOS)在基线、手术当日及术后1、2、3个月评估。
  • 受试者每两周完成一次GAD-7和PHQ-8问卷(干预组通过RxWell™应用、对照组通过REDCAP);同时记录术后并发症和资源利用数据,并每月接收随机至该组每位参与者RxWell使用与参与度报告。

关键数值与推荐

  • 入组筛选阈值:PROMIS简表焦虑4a和/或抑郁4a的T评分≥60。
  • 随机分配比例:干预组与对照组为3:1。
  • 干预组使用SuRxgWell数字认知行为干预的时间:术前1个月至术后3个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mood disorders (anxiety, depression), sleep disorders, and catastrophizing lead to increased post-operative pain perception, increase in postoperative opioid consumption, decreased engagement with physical activity, and increased resource utilization in surgical patients. Psychosocial disorders significantly affect postoperative outcome. Unfortunately, studies focused on perioperative psychological assessment and treatment are scarce. We propose to test whether digital cognitive behavioral intervention (dCBI) can help surgical patients. dCBI such as RxWell™ is a proven treatment for mood disorders in medical patients such as reducing depression in patients with inflammatory bowel disease. We hypothesize that RxWell™ will also be effective in surgical patients. This study aims to test whether RxWell™ can improve preoperative mood disorders and subsequently reduce postoperative pain and opioid requirement in patients scheduled for primary total hip and knee arthroplasty (THA, TKA). We named the trial as the SuRxgWell trial. METHODS: This is a randomized, controlled trial that will enroll primary and unilateral THA or TKA patients with anxiety and/or depression symptoms before surgery to receive the SuRxgWell dCBI program and investigate its impact on postoperative outcomes including postoperative pain, anxiety, depression, sleep disorder, and catastrophizing. After signing an informed consent, subjects will be screened using the PROMIS questionnaires, and subjects with a T-score of ≥ 60 on the short Patient-Reported Outcomes Measurement Information System (PROMIS) 4a Anxiety and/or short PROMIS 4a Depression questionnaires will be randomized to either usual care (control group) or the cognitive behavioral intervention, RxWell™, plus usual care (intervention group). The control group will receive information on how to locate tools to address anxiety and depression, whereas the intervention group will have access to SuRxgWell 1 month prior to surgery and up to 3 months after surgery. The allocation will be 3:1 (intervention to control). Investigators will be blinded, but research coordinators approaching patients and research subjects will not. The primary outcome will be day of surgery anxiety or depression symptoms measured with the PROMIS Short Form v1.0 -Anxiety 4a/Depression and Generalized Anxiety Disorder Measure (GAD-7) and Patient Health Questionnaire (PHQ-8). Secondary end points include measuring other health-related quality of life outcomes including sleep disturbance, fatigue, ability to participate in social roles, pain interference, cognitive function, pain catastrophizing, and physical function. Other secondary outcomes include collecting data about preoperative and postoperative pain scores, and pain medication usage, and orthopedic functional recovery at baseline, day of surgery, and 1, 2, and 3 months after the surgery with the Pain Catastrophizing Scale, the Knee injury and Osteoarthritis Outcome Score (KOOS), and Hip injury and Osteoarthritis Outcome Score (HOOS). In addition, subjects will be asked to complete a GAD-7 and PHQ-8 questionnaires bi-weekly (via the RxWell™ app for the interventional group or REDCAP for the control group). Data about postsurgical complications, and resource utilization will also be recorded. We will also receive monthly reports measuring the usage and engagement of RxWell use for each participant randomized to that arm. The primary hypotheses will be assessed with intention-to-treat estimates, and differences in primary outcome will be tested using independent two sample t-tests. This trial is registered to the ClinicalTrials.gov database (NCT05658796) and supported by the DAPM, UPMC Health Plan, and the NIH. DISCUSSION: Our trial will evaluate the feasibility of digital cognitive behavioral intervention as a perioperative tool to improve anxiety and depression before and after major orthopedic surgery in comparison to education. If digital cognitive behavioral intervention proves to be effective, this might have important clinical implications, reducing the incidence of chronic postsurgical pain and improving outcomes.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kaynar AM, Lin C, Sanchez AG, et al. SuRxgWell: study protocol for a randomized controlled trial of telemedicine-based digital cognitive behavioral intervention for high anxiety and depression among patients undergoing elective hip and knee arthroplasty surgery. Trials. 2023. PMID: 37946291. doi:10.1186/s13063-023-07634-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。